2 Unpopular Stocks That Deserve a Second Chance and 1 Facing Challenges [Yahoo! Finance]
Artivion, Inc. (AORT)
Company Research
Source: Yahoo! Finance
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory. At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. Keeping that in mind, here are two stocks poised to prove Wall Street wrong and one facing legitimate challenges. One Stock to Sell: Artivion (AORT) Consensus Price Target: $51.71 (15% implied return) Formerly known as CryoLife until its 2022 rebranding, Artivion (NYSE:AORT) develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. Why Does AORT Give Us Pause? Subscale operations are evident in its revenue base of $422.6 million, meaning it has fewer distribution channels than its larger rivals Poor free cash flow margin of 0.1% for the last five years limits its freedom to invest in growth i
Show less
Read more
Impact Snapshot
Event Time:
AORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AORT alerts
High impacting Artivion, Inc. news events
Weekly update
A roundup of the hottest topics
AORT
News
- Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Artivion (NYSE:AORT) Vs The Rest [Yahoo! Finance]Yahoo! Finance
- Strong Q3 Results and Raised Outlook Could Be a Game Changer for Artivion (AORT) [Yahoo! Finance]Yahoo! Finance
- Artivion (AORT): Is the Healthcare Standout Fairly Valued After Recent Surge? [Yahoo! Finance]Yahoo! Finance
- Artivion's (NYSE:AORT) Q3 Sales Top Estimates [Yahoo! Finance]Yahoo! Finance
AORT
Earnings
- 11/6/25 - Beat
AORT
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- 12/3/25 - Form 4
- AORT's page on the SEC website